Skip to content

XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Coronavirus – COVID-19 Program
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Independent Research
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Diabetic Nephropathy References

  1. Atlas of End-Stage Renal Disease. Bethesda: National Institutes of Health, NIDDK; 2005. USRDS 2005 Annual Data Report.
  2. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007 Feb; 49(2 Suppl 2):S12–154.
  3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
  4. Keen H. The Diabetes Control and Complications Trial (DCCT). Health Trends. 1994; 26(2):41–3.
  5. Schrier RW, Estacio RO, Mehler PS, Hiatt WR. Appropriate blood pressure control in hypertensive  and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol. 2007 Aug; 3(8):428–38.
  6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993 Nov 11;329(20):1456–62.
  7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20; 345(12):851–60.
  8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20; 345(12):861–9.
  9. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Semin  Nephrol. 2011 September ; 31(5): 459–465.
  10. Jalal DI, et al Serum Uric acid level predict the development of albuminuria over 6 years in patients with type I diabetes: findings from the Coronary Artery Clacification in Type I Diabetes Study, Nephropl Dial Transplant 2012; 25:1865-1869.
  11. Hovingd  P, et al Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study, Diabetes 2009;58:1668-71.
  12. Ficociello LH, et al High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. Diabetes Care 2010;33:1337-43.
  13. Goicoechia M et al, Effect of allopurinol in chronic kidney disease progression and cardiovascular risk, Clin J Am Soc Nephrol 5: 1388-1393, 2010.
  14. Siu Y-P, et al. Use of allopurinol in slowing the progression of renal disease through its ability to  lower serum uric acid level, Am J Kidney Dis 47: 51-59, 2005.

Press Releases

  • XORTX Announces Notice to Grant European Patent April 6, 2021
  • XORTX to Present at “Zoom With LD MICRO” March 16, 2021
  • XORTX to Present and Participate in the Sachs 14th Annual European Life Sciences CEO Forum 2021 March 9, 2021
  • XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection March 8, 2021
  • XORTX Confirms $1 Million in Warrant Exercise Proceeds March 2, 2021
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress